Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act-a Chance to Celebrate and Reflect.
作者信息
Gill John S, Formica Richard N, Murphy Barbara
机构信息
Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Medicine, Section of Nephrology and Department of Surgery, Section of Organ Transplantation and Immunology, Yale University School of Medicine, New Haven, Connecticut.
出版信息
J Am Soc Nephrol. 2021 Apr;32(4):774-776. doi: 10.1681/ASN.2020121811. Epub 2021 Mar 2.
Abstract
摘要
相似文献
1
Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act-a Chance to Celebrate and Reflect.《肾脏移植患者全面免疫抑制药物保险覆盖法案》的通过——一个值得庆祝和反思的契机。
J Am Soc Nephrol. 2021 Apr;32(4):774-776. doi: 10.1681/ASN.2020121811. Epub 2021 Mar 2.
2
Addendum: Passage of the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act-a Chance to Celebrate and Reflect.附录：《肾移植患者综合免疫抑制药物保险法案》的通过——一个值得庆祝和反思的契机。
J Am Soc Nephrol. 2021 Jun 1;32(6):1540. doi: 10.1681/ASN.2021030427.
3
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.在当前时代，扩大医疗保险免疫抑制药物覆盖范围以惠及肾移植受者的经济评估。
J Am Soc Nephrol. 2020 Jan;31(1):218-228. doi: 10.1681/ASN.2019070646. Epub 2019 Nov 8.
4
Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant.将医疗保险对免疫抑制药物的覆盖范围延长至肾移植受者终身的成本效益。
Am J Transplant. 2004 Oct;4(10):1703-8. doi: 10.1111/j.1600-6143.2004.00565.x.
5
Cost-effectiveness of Medicare's coverage of immunosuppression medications for kidney transplant recipients.医疗保险对肾移植受者免疫抑制药物覆盖的成本效益。
Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):435-44. doi: 10.1586/erp.09.52.
6
Immunosuppression considerations in simultaneous organ transplant.同时进行器官移植的免疫抑制考虑因素。
Pharmacotherapy. 2021 Jan;41(1):59-76. doi: 10.1002/phar.2495. Epub 2021 Jan 24.
7
Drug insight: maintenance immunosuppression in kidney transplant recipients.药物洞察：肾移植受者的维持性免疫抑制
Nat Clin Pract Nephrol. 2006 Dec;2(12):688-99. doi: 10.1038/ncpneph0343.
8
Immunosuppression in Kidney Transplantation: State of the Art and Current Protocols.肾移植中的免疫抑制：最新技术和当前方案。
Curr Pharm Des. 2020;26(28):3440-3450. doi: 10.2174/1381612826666200521142448.
9
Immunosuppression Therapy in Kidney Transplantation.肾移植中的免疫抑制治疗。
Urol Clin North Am. 2022 May;49(2):345-360. doi: 10.1016/j.ucl.2021.12.010.
10
A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT.一项多中心、患者和评估者双盲、非劣效性、随机对照的 II 期临床试验，旨在比较标准和扭矩 Teno 病毒导向免疫抑制在移植后第一年的肾移植受者中的效果：TTVguideIT。
Trials. 2023 Mar 22;24(1):213. doi: 10.1186/s13063-023-07216-0.
引用本文的文献
1
Racial Equity in Living Donor Kidney Transplant Centers, 2008-2018.2008-2018 年活体供肾移植中心的种族公平性。
JAMA Netw Open. 2023 Dec 1;6(12):e2347826. doi: 10.1001/jamanetworkopen.2023.47826.
2
Racial and ethnic disparities in psychosocial evaluation and liver transplant waitlisting.心理社会评估和肝移植候补名单中的种族和民族差异。
Am J Transplant. 2023 Jun;23(6):776-785. doi: 10.1016/j.ajt.2023.01.011. Epub 2023 Jan 31.
3
Nanotherapeutics in transplantation: How do we get to clinical implementation?移植中的纳米治疗学：我们如何实现临床应用？
Am J Transplant. 2022 May;22(5):1293-1298. doi: 10.1111/ajt.17012. Epub 2022 Mar 10.
Zotero 插件